Tarek Mekhail
- Pulmonary and Respiratory Medicine top 0.1%
- Oncology top 0.2%
- Molecular Biology top 2%
- Cancer Research top 0.5%
- Biomedical Engineering top 2%
- Co-authors
- Federico CappuzzoEnriqueta FelipRonald M. BukowskiDong‐Wan KimBenjamin SolomonYi‐Long WuTiziana UsariTony Mok
- Topics
- Lung Cancer Treatments and Mutations (84 papers)Lung Cancer Research Studies (40 papers)Lung Cancer Diagnosis and Treatment (38 papers)
- Partner nations
- United StatesSouth KoreaSpain
In The Last Decade
Tarek Mekhail
168 papers receiving 10.4k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Pulmonary and Respiratory Medicine 6.9k
- Oncology 5.8k
- Molecular Biology 3.0k
- Cancer Research 1.8k
- Biomedical Engineering 995
Countries citing papers authored by Tarek Mekhail
This map shows the geographic impact of Tarek Mekhail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Mekhail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Mekhail more than expected).
Fields of papers citing papers by Tarek Mekhail
This network shows the impact of papers produced by Tarek Mekhail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Mekhail. The network helps show where Tarek Mekhail may publish in the future.
Co-authorship network of co-authors of Tarek Mekhail
This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Mekhail. A scholar is included among the top collaborators of Tarek Mekhail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Mekhail. Tarek Mekhail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | 18 | |
| 6 | 1 | |
| 7 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 1137 |
| 8 | 1 | |
| 9 | 10 | |
| 10 | Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC | 1 |
| 11 | 73 | |
| 12 | 104 | |
| 13 | 10 | |
| 14 | 3 | |
| 15 | 11 | |
| 16 | 13 | |
| 17 | 266 | |
| 18 | 34 | |
| 19 | Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breathbreakdown → | 483 |
| 20 | 7 |
About Tarek Mekhail
Tarek Mekhail is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 170 papers that have together received 10.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (40 papers) and Lung Cancer Diagnosis and Treatment (38 papers). The work is most often cited by research in Oncology (5.8k citations), Pulmonary and Respiratory Medicine (6.9k citations) and Cancer Research (1.8k citations). Tarek Mekhail has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Federico Cappuzzo, Enriqueta Felip, Ronald M. Bukowski, Dong‐Wan Kim, Benjamin Solomon, Yi‐Long Wu, Tiziana Usari, Tony Mok, Kazuhiko Nakagawa and Jolanda Paolini. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.